



Proteomics International

LABORATORIES LTD

ASX Release

21 October 2026

ASX code: PIQ

Proteomics International receives \$2.0 million in R&D tax incentive

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce that its cash reserves have been strengthened by the receipt of a \$2.0 million research and development (R&D) tax incentive for the 2025-26 financial year.

The Federal R&D tax incentive encourages companies engaging in research beneficial to Australia by providing a cash rebate of 43.5% for eligible expenditure on qualifying activities. In the 2025-26 financial year, Proteomics International Laboratories Ltd and its subsidiaries incurred \$4.6 million of eligible R&D expenditure, enabling the Company to receive a \$2.0 million rebate.

Authorised by the Chair of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

David Morris
CEO and Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Jane Lowe
Investor Relations
IR Department
T: +61 411 117 774
E: jane.lowe@irdepartment.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com